Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03580681
Other study ID # WCCR-ARTH-4
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 22, 2018
Est. completion date June 1, 2020

Study information

Verified date June 2021
Source Physicians Committee for Responsible Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess whether, in individuals with rheumatoid arthritis, a low-fat, vegan diet improves pain and other subjective symptoms more effectively than a control supplement or a placebo. The principal measure is pain as measured by Visual Analog Scale (VAS) and disease activity as measured by number of painful swollen and tender joints, respectively. The study duration is 36 weeks. This study tests that a low fat, plant-based (vegan) diet free of foods commonly identified as triggers improves mood, using the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Depression Inventory II (BDI-II).


Description:

Preliminary evidence suggests that low-fat, vegetarian diets and certain nutritional supplements can help reduce pain and also reduce the need for pain medications for some people. The investigators will ask about 100 people to participate. All of them will get a low-fat, vegan diet and a nutritional supplement (mixture of omega-3 oils and vitamin E or a placebo), although some will get the diet first, and others will get the supplement first. This order in which they will get the diet and the supplement will be determined randomly, that is, by chance (like the toss of a coin). The principal measure is pain as measured by Visual Analog Scale (VAS) and disease activity as measured by number of painful swollen and tender joints, respectively. The Beck Depression Inventory II (BDI-II)will be used to measure changes in mood. The study duration is 36 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 2
Est. completion date June 1, 2020
Est. primary completion date June 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - A diagnosis of rheumatoid arthritis based on 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria. Classification as "definite RA" is based on: - the confirmed presence of synovitis in at least 1 joint - absence of an alternative diagnosis that better explains the synovitis - and achievement of a total score of 6 or greater (of a possible 10): 24 Joint involvement, designating the metacarpophalangeal joints, proximal interphalangeal joints, the interphalangeal joint of the thumb, second through third metatarsophalangeal joint and wrist as small joints, and elbows, hip joints and knees as large joints: 1. Involvement of 1 large joint gives 0 points 2. Involvement of 2-10 large joints gives 1 point 3. Involvement of 1-3 small joints (with or without involvement of large joints) gives 2 points 4. Involvement of 4-10 small joints (with or without involvement of large joints) gives 3 points 5. Involvement of more than 10 joints (with involvement of at least 1 small joint) gives 5 points - Serological parameters - including the rheumatoid factor as well as anti-citrullinated protein antibody (ACPA): 1. Negative RF and negative ACPA gives 0 points 2. Low-positive RF or low-positive ACPA gives 2 points 3. High-positive RF or high-positive ACPA gives 3 points Acute phase reactants: 1 point for elevated erythrocyte sedimentation rate (ESR) or elevated C-reactive protein (CRP) value Duration of arthritis: 1 point for symptoms lasting six weeks or longer - Continuing or recurring pain (i.e., joint pain daily, unless on pain medication). - Age at least 18 years - Ability and willingness to participate in all components of the study - Willingness to be assigned to either the diet group or supplement group - Pain medications unchanged within last 6 weeks. Exclusion Criteria: - < 18 years of age - Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use - Use of recreational drugs in the past 6 months (past drug use, if fully recovered, is not a criteria for exclusion) - Pregnancy - Unstable medical or psychiatric illness - Likely to be disruptive in group sessions (as determined by research staff) - Already following a low-fat, vegan diet - Lack of English fluency - Inability to maintain current medication regimen - Inability or unwillingness to participate in all components of the study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Plant-based diet
Weekly instructions will be given to the participants in the intervention group about following vegan diet.
Dietary Supplement:
Supplement
Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E

Locations

Country Name City State
United States Physicians Committee for Responsible Medicine Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Physicians Committee for Responsible Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Score will be measured by visual analog scale from 0%, indicating no pain, to 100%, indicating pain as bad as it could possibly be Change in pain score from Baseline at 4 months
Primary Disease Activity score measured by number of painful, swollen and tender joints from scores below 2.6, indicating disease remission, to more than 5.1, indicating severe disease activity. Change in disease activity score from Baseline at 4 months
Primary Improvement in mood measured by the Beck Depression Inventory II (BDI-II), with scores ranging from 0 indicating minimal depression to 63, indicating severe depression. Change in mood from Baseline at 4 months
Secondary Quality of Life of Mood measured by a Modified Health Assessment Questionnaire (MHAQ). The questionnaire measures the difficulty level of performing 8 different activities. A score of 0 = the activity can be performed without difficulty. A score of 3 = the activity cannot be performed. The MHAQ is calculated as the average of these scores in order to determine overall quality of life. Change in quality of life from Baseline at 4 months
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4